Eli Lilly and Company, Gilead Sciences, Vertex Pharmaceuticals, Novo Nordisk A/S, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, manufacturing and marketing of prescription drugs, vaccines and other medical therapies. These stocks give investors partial ownership in those firms, whose value is driven by factors such as clinical-trial outcomes, regulatory approvals, patent lifecycles and broader healthcare trends. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY traded down $15.71 on Friday, hitting $625.15. The company's stock had a trading volume of 14,089,857 shares, compared to its average volume of 4,833,475. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. The firm's fifty day moving average price is $774.10 and its 200-day moving average price is $799.11. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $972.53. The firm has a market capitalization of $592.48 billion, a price-to-earnings ratio of 40.86, a P/E/G ratio of 0.89 and a beta of 0.44.
Read Our Latest Research Report on LLY
Gilead Sciences (GILD)
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
NASDAQ GILD traded up $9.13 during trading on Friday, hitting $119.41. The stock had a trading volume of 13,112,190 shares, compared to its average volume of 5,807,634. The company has a market capitalization of $148.54 billion, a PE ratio of 23.79, a P/E/G ratio of 0.75 and a beta of 0.33. The company's 50-day moving average price is $110.93 and its two-hundred day moving average price is $107.53. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. Gilead Sciences has a 12 month low of $72.43 and a 12 month high of $121.38.
Read Our Latest Research Report on GILD
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
NASDAQ VRTX traded down $9.09 during trading on Friday, hitting $366.54. The stock had a trading volume of 3,679,339 shares, compared to its average volume of 1,989,627. The company has a market capitalization of $93.98 billion, a PE ratio of 26.20 and a beta of 0.44. The company's 50-day moving average price is $450.77 and its two-hundred day moving average price is $465.77. Vertex Pharmaceuticals has a 12 month low of $364.66 and a 12 month high of $519.88.
Read Our Latest Research Report on VRTX
Novo Nordisk A/S (NVO)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
NYSE NVO traded up $2.30 during trading on Friday, hitting $51.06. The stock had a trading volume of 23,312,357 shares, compared to its average volume of 23,928,642. The company has a market capitalization of $227.98 billion, a PE ratio of 14.03, a P/E/G ratio of 1.54 and a beta of 0.63. The company's 50-day moving average price is $67.14 and its two-hundred day moving average price is $71.54. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $139.74.
Read Our Latest Research Report on NVO
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Shares of Pfizer stock traded up $0.34 on Friday, reaching $24.57. 36,356,648 shares of the company were exchanged, compared to its average volume of 46,490,120. Pfizer has a one year low of $20.92 and a one year high of $30.43. The company has a market capitalization of $139.69 billion, a price-to-earnings ratio of 13.07, a PEG ratio of 0.89 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.96 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average of $24.44 and a 200 day moving average of $24.49.
Read Our Latest Research Report on PFE
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
MarketBeat All Access Sale